1432514-50-5

Basic information

• Product Name: N-(2,4-dimethoxybenzyl)-2-oxo-N-(1,2,4-thiadiazol-5-yl)-2,3-dihydro-1,3-benzoxazole-6-sulfonamide
• Synonyms: N-(2,4-dimethoxybenzyl)-2-oxo-N-(1,2,4-thiadiazol-5-yl)-2,3-dihydro-1,3-benzoxazole-6-sulfonamide
• CAS NO: 1432514-50-5
• Molecular Weight: 448.48
• Mol File: 1432514-50-5.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: N-(2,4-dimethoxybenzyl)-2-oxo-N-(1,2,4-thiadiazol-5-yl)-2,3-dihydro-1,3-benzoxazole-6-sulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(2,4-dimethoxybenzyl)-2-oxo-N-(1,2,4-thiadiazol-5-yl)-2,3-dihydro-1,3-benzoxazole-6-sulfonamide(1432514-50-5)
• EPA Substance Registry System: N-(2,4-dimethoxybenzyl)-2-oxo-N-(1,2,4-thiadiazol-5-yl)-2,3-dihydro-1,3-benzoxazole-6-sulfonamide(1432514-50-5)

Safety Data

• Hazardous Substances Data: 1432514-50-5(Hazardous Substances Data)

Upstream product

• 613-45-6 2,4-Dimethoxybenzaldehyde 
• 27685-90-1 2-oxo-2,3-dihydrobenzo[d]oxazole-6-sulfonyl chloride 
• 1063733-41-4 N-[(2,4-dimethoxyphenyl)methyl]-1,2,4-thiadiazol-5-amine 

Downstream Products

• 1432515-16-6 (R)-N-(2,4-dimethoxybenzyl)-3-(3-fluoro-1-phenylpropyl)-2-oxo-N-(1,2,4-thiadiazol-5-yl)-2,3-dihydrobenzo[d]oxazole-6-sulfonamide 
• 1432513-88-6 C₁₈H₁₅FN₄O₄S₂ 
• 1432515-21-3 N-(2,4-dimethoxybenzyl)-2-oxo-N-(1,3-thiazol-2-yl)-2,3-dihydrobenzo[d]oxazole-6-sulfonamide 
• 1432514-54-9 tert-butyl-8-[(1R)-1-{6-[(2,4-dimethoxybenzyl)(1,2,4-thiadiazol-5-yl)sulfamoyl]-2-oxo-1,3-benzoxazol-3(2H)-yl}ethyl]-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 1432515-15-5 (R)-N-(2,4-dimethoxybenzyl)-3-(3-hydroxy-1-phenylpropyl)-2-oxo-N-(1,2,4-thiadiazol-5-yl)-2,3-dihydrobenzo[d]oxazole-6-sulfonamide 
• 1432514-51-6 C₃₃H₃₅N₅O₈S₂ 

Relevant articles and documents

Benzoxazolinone aryl sulfonamides as potent, selective Nav1.7 inhibitors with in vivo efficacy in a preclinical pain model

Studies on human genetics have suggested that inhibitors of the Nav1.7 voltage-gated sodium channel hold considerable promise as therapies for the treatment of chronic pain syndromes. Herein, we report novel, peripherally-restricted benzoxazoli